Clinical trials: Lung Metastasis
Lung Cancer
Comparison of 22-gauge and 19-gauge Aspiration Needle During EBUS-TBNA
Investigators intend to compare the 19-gauge needle and the 22-gauge-needle during EBUS-TBNA concerning the diagnostic yield, the quality and quantity of each biopsy needle without raising the rate of complications.
- Trial name
- NCT02813603
- Testing
- EBUS
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Essen
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- RIOT 4B (NCT07443020)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Lung Cancer, Lung Cancer Metastatic
Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of Vascular Endothelial Growth Factor Receptor 2（VEGFR）、FGFR（Fibroblast Growth Factor Receptor）, Platelet-derived growth factor…
- Trial name
- NCT03703596
- Testing
- Anlotinib Hydrochloride, Docetaxel
- Where
- 10 sites in China
- Volunteers
- 88 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Non Small Cell Lung Cancer
Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC
This trial will evaluate whether the sequential administration of Cisplatin/Vinorelbine/Bevacizumab followed by Docetaxel/Gemcitabine/Bevacizumab versus the Cisplatin/Docetaxel/Bevacizumab combination as first line treatment…
- Trial name
- NCT00620971
- Testing
- Vinorelbine, Cisplatin, Bevacizumab
- Where
- 9 sites in Greece
- Volunteers
- 77 people
- Sponsor
- Hellenic Oncology Research Group
Non-small-cell Lung Cancer
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT01138163
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 121 people
- Sponsor
- Peregrine Pharmaceuticals
Non-small Cell Lung Cancer
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT05880706
- Testing
- BL-B01D1, Osimertinib Mesylate Tablets
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus…
- Trial name
- NCT07246863
- Testing
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab
- Where
- 36 sites in United States, Germany and 5 more
- Volunteers
- 131 people
- Sponsor
- CatalYm GmbH
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Breast Cancer Nos Metastatic Recurrent, Early Lung Cancer
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer.
- Trial name
- CANTO (NCT01993498)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 14,750 people
- Sponsor
- UNICANCER
Non-Small Cell Lung Carcinoma
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
This study is to assess the efficacy of IMRT combined with erlotinib compared with whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain metastases.
- Trial name
- NCT02556593
- Testing
- IMRT, WBRT, erlotinib
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-sen University
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary…
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
- Trial name
- NCT05235165
- Testing
- Biospecimen Collection, Computed Tomography, Questionnaire Administration
- Where
- 233 sites in United States, Australia and 4 more
- Volunteers
- 62 people
- Sponsor
- Children's Oncology Group
Lung Cancer
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
Immunotherapy is probably, since the development of therapies targeting EGFR mutations or ALK rearrangement, the most attractive therapeutic perspective in the management of metastatic lung cancer.
- Trial name
- IMMUNO-PREDICT (NCT02827344)
- Testing
- blood sample collection for CTC and MDSC analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Solid Tumor, Non-Small Cell Lung Cancer Metastatic
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer
- Trial name
- NCT02959619
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
NSCLC
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093.
- Trial name
- NCT04077099
- Testing
- REGN5093
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 95 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small-Cell Lung Cancer, Brain Metastases
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
- Trial name
- NCT06476093
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Brain Metastases, Non-small Cell Lung Cancer
Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC
WBRT (whole-brain radiation therapy) exhibits poor tumor control and decreased NCF (neurocognitive function). Herein, we investigated the safety and efficacy of HA-WBRT+SIB (hippocampus-avoidance whole-brain radiation therapy…
- Trial name
- NCT06557187
- Testing
- ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yatian Liu
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.